Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | SORD | Q00796 | 2/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954009 | 0.80 | TRPV1 (0.47) | HRH3SORDPDE10AHRH4CNR2 | |
| SCHEMBL27454974 | 0.80 | HRH3 (0.66) | HRH3SORDHRH4ROCK2 | |
| SCHEMBL30954035 | 0.80 | HRH3 (0.66) | HRH3SORDHRH4ROCK2 | |
| SCHEMBL26618088 | 0.80 | TRPV1 (0.47) | HRH3SORDPDE10AHRH4CNR2 | |
| SCHEMBL21812367 | 0.77 | ADRB1 (0.39) | HRH4CNR2ACACB | |
| SCHEMBL31346241 | 0.77 | ADRB1 (0.39) | HRH4CNR2ACACB | |
| SCHEMBL21914804 | 0.76 | PIK3CA (0.50) | SORDALDH1A1GAASMN1; SMN2 | |
| SCHEMBL29790016 | 0.76 | PIK3CA (0.50) | SORDALDH1A1GAASMN1; SMN2 | |
| SCHEMBL27457780 | 0.75 | PTGER4 (0.45) | HRH3SORDTRPV3HRH4ROCK2 | |
| SCHEMBL17619976 | 0.75 | GRIN2D (0.50) | TRPV3PDE10ACNR2ALDH1A1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522593-B2 | Azacycloalkyl carbonyl cyclic amine compound | ALIVEXIS, INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | ALIVEXIS, INC. (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4538264-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | Alivexis, Inc. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119317620-A | Azacycloalkyl carbonyl cyclic amine compounds | 亚力维克希斯股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023243601-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | モジュラス株式会社 | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | NCF1, ELANE, MPO | HRH3 509/4885SORD 2200/4885TRPV3 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.